AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2

Switsita M Tablet

Prescription Icon
Prescription Required

Marketer

Lifecare Neuro Products Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Switsita M Tablet

DiabetiCare Duo tablets combine two medications to effectively manage elevated blood glucose in individuals with type 2 diabetes. This dual action helps mitigate serious diabetic complications like vision impairment and kidney dysfunction, potentially lowering the risk of cardiovascular events such as stroke or heart attack. DiabetiCare Duo may be prescribed independently or in conjunction with other antidiabetic therapies. Optimal results are achieved when combined with a balanced diet and regular physical activity. Dosage is personalized based on individual health status, blood glucose levels, and concurrent medications. Consuming the tablets with food minimizes gastrointestinal discomfort. Consistent daily dosing at the same time maximizes therapeutic benefit; discontinuation should only occur under medical supervision. Adherence to the prescribed diet and exercise regimen is crucial for successful diabetes management; lifestyle choices significantly impact disease control. Commonly reported side effects include nausea, diarrhea, vomiting, stomach upset, headache, and pharyngitis. Hypoglycemia is a potential adverse effect, particularly when used with insulin or sulfonylureas; patients should be familiar with its symptoms and management. This medication isn't universally suitable. Prior to commencing treatment, inform your physician of any pre-existing conditions such as liver, kidney, or heart disease, pancreatic issues, or significant alcohol consumption. Pregnant or lactating women should seek medical advice before use. Potential drug interactions exist; disclose all medications to your doctor to ensure treatment safety. Alcohol should be limited due to its hypoglycemic effects. Your doctor will monitor kidney function and blood glucose levels throughout treatment.

Uses of Switsita M Tablet

Managing type 2 diabetes

Major Benefits of Switsita M Tablet:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Switsita M Tablets should be administered with a meal.

Common Side effects of Switsita M Tablet:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Switsita M Tablet:

Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Switsita M Tablets should be administered with a meal.

How Switsita M Tablet works:

Switsita M Tablet combines sitagliptin and metformin to manage blood sugar. Sitagliptin enhances insulin production by the pancreas, improves insulin utilization, and reduces hepatic glucose output. Metformin, a biguanide, decreases liver glucose production, slows intestinal glucose absorption, and enhances insulin sensitivity. This dual action leads to superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Consuming alcohol while taking Switsita M Tablet is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Switsita M Tablet during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the potential benefits against any possible risks prior to prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The use of Switsita M Tablet while breastfeeding is likely inadvisable. Preliminary human research indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Exercise caution when administering Switsita M Tablet to individuals with impaired kidney function; dosage modification may be necessary. Consult a physician for guidance. Switsita M Tablet is contraindicated in patients exhibiting severe kidney disease. Routine monitoring of renal function is recommended during treatment.

LiverLiverUNSAFE

Use of Switsita M Tablet is contraindicated in individuals with hepatic impairment; it should be avoided. Physician consultation is recommended.

What if you forget to take Switsita M Tablet :

Should you forget a Switsita M Tablet dose, take it promptly. Nevertheless, if your next dose is imminent, omit the missed dose and resume your usual dosing pattern. Avoid taking a double dose.

Facts to Know About Switsita M Tablet

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Switsita M Tablet

Switsita M Tablet combines sitagliptin and metformin to treat type 2 diabetes mellitus in adults. This combination improves blood glucose control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18 years old.
Prolonged Switsita M Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, neurological issues (tingling, numbness in extremities, weakness, urinary problems, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Switsita M Tablet may cause common side effects such as low blood sugar (hypoglycemia), taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Switsita M Tablet is contraindicated in patients with hypersensitivity to its components or excipients, and in those with severe renal or hepatic impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Switsita M Tablet with alcohol is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container, following the storage instructions on the packaging. Discard any unused medication and keep it out of reach of children, pets, and others.
Switsita M Tablet (containing metformin) can cause lactic acidosis, a serious medical emergency resulting from excessive blood lactic acid (also known as MALA). This rare side effect necessitates caution in patients with kidney disease, the elderly, or those who consume significant alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Switsita M and seek immediate medical attention.
Switsita M Tablet combines sitagliptin and metformin to manage type 2 diabetes in adults. This medication improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. It's not suitable for individuals under 18.
Switsita M Tablet may cause common side effects including low blood sugar (hypoglycemia), altered taste, nausea, stomach ache, diarrhea, headache, and upper respiratory infections. Rare but serious side effects such as lactic acidosis may occur. Prolonged use can also result in vitamin B12 deficiency.
Switsita M Tablets are contraindicated in patients with allergies to any of its components or excipients, and in those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Switsita M Tablet with alcohol is unsafe and may heighten the risk of lactic acidosis.
Switsita M Tablet (containing metformin) can cause lactic acidosis, a serious medical emergency characterized by high blood lactic acid levels (also known as MALA). This rare side effect necessitates caution in patients with kidney disease, older adults, or those who consume excessive alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If experienced, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged Switsita M Tablet use can lead to vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, annual supplemental vitamin B12 intake is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and ensure it's inaccessible to children, pets, and others.
Switsita M Tablet combines sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. It's not suitable for individuals under 18.
Switsita M Tablet may cause common side effects such as hypoglycemia, taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Switsita M Tablet is contraindicated in patients with hypersensitivity to any of its components. Its use should also be avoided in those with severe renal or hepatic impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Switsita M Tablet and alcohol is unsafe and may heighten the risk of lactic acidosis.
Switsita M Tablet (containing metformin) can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as MALA). This rare side effect necessitates avoiding metformin use in patients with kidney disease, the elderly, or those who consume significant alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If these occur, discontinue Switsita M and seek immediate medical attention.
Prolonged Switsita M Tablet use can lead to vitamin B12 deficiency by hindering its stomach absorption. This deficiency, if left unaddressed, may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), necessitating supplemental vitamin B12, ideally annually, according to some studies.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and ensure it's inaccessible to children, pets, and others.
Switsita M Tablet
137